ERAP2 overexpression is a marker for reduced anti-PD-1 response in nasopharyngeal carcinoma.
Invited conference paper presented and published in conference proceedings


Times Cited
Web of Science0WOS source URL (as at 18/06/2021) Click here for the latest count
Altmetrics Information
.

Other information
AbstractNasopharyngeal carcinoma (NPC) is an EBV-associated epithelial cancer common in the Southern Chinese population. Patients with recurrent or metastatic NPC treated with PD-1 blockade showed a response rate of 20.5%, with no correlation observed between the expression of PD-L1 and treatment response. In an effort to identify biomarkers for anti-PD-1 treatment response, we evaluated a cohort of 10 NPC patients with recurrent or metastatic NPC treated with nivolumab or pembrolizumab. Laser capture microdissection was performed on pretreatment biopsies, with tumor and microenvironment compartments separately microdissected. Nasopharyngeal epithelium from normal nasopharyngeal biopsies were also microdissected as controls. Smart-3SEQ, a novel 3´ end RNA-Seq technique that allows for the accurate quantification of transcript abundance in FFPE samples, was performed to obtain gene expression libraries. ERAP2, a zinc metalloaminopeptidase that performs N-terminal trimming of antigenic epitopes for presentation by MHC class I, was among the most highly upregulated genes in the tumor compartment of nonresponders (adjusted p = 0.033). ERAP2 overexpression was also observed in NPC tumors compared to normal controls. Immunohistochemistry validated the overexpression of ERAP2 in nonresponders, while responders had similar expression to normal controls. In conclusion, ERAP2 is overexpressed in NPC tumors and is a promising biomarker for reduced anti-PD-1 response in NPC.
Acceptance Date01/11/2019
All Author(s) ListTay JK, Ma BBY, Varma S, Lim YC, Tan CS, Lo KW, Sunwoo JB, Cullen KJ, Goh BC, West RB
Name of ConferenceAACR Special Conference on Tumor Immunology and Immunotherapy
Start Date of Conference17/11/2019
End Date of Conference20/11/2019
Place of ConferenceBoston
Country/Region of ConferenceUnited States of America
Title of PublicationCANCER IMMUNOLOGY RESEARCH
Year2020
Month3
Volume Number8
Issue NumberSippl 3
PublisherAMER ASSOC CANCER RESEARCH
Place of PublicationBoston
Pages99 - 99
ISSN2326-6066
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology;Immunology;Oncology;Immunology

Last updated on 2021-19-06 at 00:27